There’s been some debate in recent years about the true value and effectiveness of certain types of cancer screenings. This is, of course, a perfectly reasonable thing to be doing both in the name of advancing medical science, and especially in an environment where there's so much downward pressure on the costs of healthcare.
If your chair was cold, I knew you were two floors down in the NICU cradling your only child – the only one I’d be able to give you – making sure his IV and nutrition lines were also connected and beeping lively and skipping at the same beat as mine.
Having been a caregiver to my late husband who died from cancer, I know first-hand the difficulties of caregiving — not to mention what it must be like for those trying to do it during a worldwide pandemic.
Superior progression-free survival (PFS) was seen in patients with ovarian cancer who previously had a partial response (PR) to platinum-based therapy when they took Zejula (niraparib). This response was seen in patients with or without germline BRCA mutations, according to data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.
This essay was written by her colleagues, Jeanine Gordon and Jaclyn Andronico, Memorial Sloan Kettering Cancer Center, nominating Lisa Klempner, M.S.N., RN, OCN for CURE®’s 2019 Extraordinary Healer® Award.